Villa M, Durand-Gorde J M, Carayon P, Ruf J
Unité 38 de I'Institut National de la Santé et de la Recherche Médicale, Faculté de Médecine, Marseille, France.
J Autoimmun. 1996 Oct;9(5):653-60. doi: 10.1006/jaut.1996.0085.
We have previously established that thyroperoxidase (TPO), a major thyroid antigen involved in autoimmune thyroid diseases, interacts with an idiotype present on human and mouse antibodies directed to thryoglobulin (TG), another thyroid autoantigen. In order to characterize the TPO-reactive idiotype, we selected a TG monoclonal antibody (mAb J7 B49.15) which bound to TPO and cross-reacted with human bispecific TG and TPO autoantibodies (TGPO aAb) for both TG and TPO binding. The TPO-reactive structure of the mAb J7 B49.15 was present on the F(ab')2, located next to the TG binding site and dependent on the association of the heavy and light chains. We found that mAb J7 B49.15 shared a TPO-reactive idiotypic structure with TG mAb from the same cluster of TG reactivity. All the mAb from this cluster were directed to an immunodominant region of TG, recognized by TG aAb. Natural anti-idiotypes from pooled normal human IgG used as a therapeutic intravenous preparation inhibited the TPO binding to mAb J7 B49.15. By homologous immunization in BALB/c mice, mAb J7 B49.15 induced an antiserum with both TG and TPO reactivities. Whereas TG reactivity decreased as early as day 14 post-immunization, TPO reactivity remained at a plateau value from day 21 to day 42. The TG and TPO reactive antisera were shown to inhibit the binding of mAb J7 B49.15 to TG and TPO, respectively. We concluded that mAb J7 B49.15 reacted with TPO through an interspecies idiotype which appeared conformational and related to the epitopic specificity of the mAb. Interestingly, this idiotype would carry the internal image of a TG structure able to induce, in homologous system, a TG antibody response followed by a TPO response without the need of any immunizing antigen.
我们先前已经证实,甲状腺过氧化物酶(TPO)是参与自身免疫性甲状腺疾病的一种主要甲状腺抗原,它可与针对另一种甲状腺自身抗原甲状腺球蛋白(TG)的人源和鼠源抗体上存在的独特型发生相互作用。为了对TPO反应性独特型进行表征,我们选择了一种TG单克隆抗体(mAb J7 B49.15),该抗体与TPO结合,并与人类双特异性TG和TPO自身抗体(TGPO aAb)在TG和TPO结合方面发生交叉反应。mAb J7 B49.15的TPO反应性结构存在于F(ab')2上,位于TG结合位点旁边,且依赖于重链和轻链的缔合。我们发现mAb J7 B49.15与来自相同TG反应性簇的TG单克隆抗体共享一种TPO反应性独特型结构。该簇中的所有单克隆抗体均针对TG的一个免疫显性区域,该区域可被TG自身抗体识别。用作治疗性静脉制剂的汇集正常人IgG中的天然抗独特型抗体可抑制TPO与mAb J7 B49.15的结合。通过在BALB/c小鼠中进行同源免疫,mAb J7 B49.15诱导出一种具有TG和TPO反应性的抗血清。尽管早在免疫后第14天TG反应性就开始下降,但TPO反应性在第21天至第42天保持在一个稳定值。已证明TG反应性抗血清和TPO反应性抗血清分别抑制mAb J7 B49.15与TG和TPO的结合。我们得出结论,mAb J7 B49.15通过一种种间独特型与TPO发生反应,该独特型似乎是构象性的,并且与单克隆抗体的表位特异性相关。有趣的是,这种独特型将携带一种TG结构的内影像,该结构能够在同源系统中诱导TG抗体反应,随后诱导TPO反应,而无需任何免疫抗原。